XW043H5 ICD-10-PCS Code: Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
Introduce Tocilizumab in Central Vein, Perc, New Tech 5
Axis Breakdown
Every ICD-10-PCS code is exactly seven characters, one per axis. Each character's meaning is defined by its position in the code.
| Position | Value | Meaning |
|---|---|---|
| 1 | SectionX | New Technology |
| 2 | Body SystemW | Anatomical Regions |
| 3 | Root Operation0 | Introduction Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| 4 | Body Part4 | Central Vein |
| 5 | Approach3 | Percutaneous |
| 6 | Device / Substance / TechnologyH | Tocilizumab |
| 7 | New Technology Group5 | New Technology Group 5 |
Related Codes
Same operation — other Body Part
Same table and root operation, differing only in the body part character.
Same operation — other Device / Substance / Technology
Same table and root operation, differing only in the device / substance / technology character.
XW043E5 — Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5, XW043F5 — Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5, XW043G5 — Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5, XW043Q5 — Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5, XW043S5 — Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5, XW043W5 — Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5
Same operation — other Qualifier
Same table and root operation, differing only in the qualifier character.
XW043H6 — Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6, XW043H7 — Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
Same procedure category (CCSR), other tables
AHRQ's Clinical Classifications Software Refined groups these ICD-10-PCS procedures with this one under Potential COVID-19 therapies (Administration of Therapeutic Substances); listed here are the members in other PCS tables. Source: Clinical Classifications Software Refined (CCSR), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, November 2025.
XW13325 — Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5, XW14325 — Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5
Contextual Map
Every relationship of XW043H5 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
PCS table
- XW0[PCS table]— CMS ICD-10-PCS tables
- New Technology — Section: New Technology[Section]: “New Technology”— CMS ICD-10-PCS tables
- Anatomical Regions — Body System: Anatomical Regions[Body System]: “Anatomical Regions”— CMS ICD-10-PCS tables
- Introduction — Operation: Introduction[Operation]: “Introduction”— CMS ICD-10-PCS tables
Clinical classification (CCSR)
- ADM019 — Potential COVID-19 therapies[CCSR category]: “Potential COVID-19 therapies — Administration of Therapeutic Substances”— AHRQ CCSR for ICD-10-PCS Procedures (HCUP) · v2026.1
Nearest codes
- XW033H5 — Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
- XW043E5 — Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
- XW043F5 — Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
- XW043G5 — Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
- XW043H6 — Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6[One axis away]— CMS ICD-10-PCS tables
- XW043H7 — Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7[One axis away]— CMS ICD-10-PCS tables
- XW043Q5 — Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
- XW043S5 — Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5[One axis away]— CMS ICD-10-PCS tables
Change history
- FY2020 (August) — Added to the code set[Change history]— CMS release files (code change ledger) · icd10pcs-fy2020aug
Change history
- FY2020 (August) — August 1, 2020Added to the code setIntroduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5FY2020 (August) changes
Read from: CMS ICD-10-PCS code tables, index and definitions — FY2027; CMS MS-DRG Definitions Manual (incl. Appendix B diagnosis index, Appendix C CC/MCC list, Appendix E procedure index) and IPPS Final Rule tables — v44; AHRQ HCUP Clinical Classifications Software Refined for ICD-10-PCS Procedures (hcup-us.ahrq.gov/toolssoftware/ccsr/PRCCSR_v2026-1.zip) — v2026.1. All data sources · How to read the labels · How MedCoder verifies its implementation
Current data releases:ICD-10-CM FY2027 · ICD-10-PCS FY2027 · HCPCS October 2026 · MS-DRG v44 · Medicare Code Editor v44.0 · NCCI PTP Q4 2026 · MUE Q4 2026 · NCD code lists 2026-01 · LCD export September 28, 2026 · All releases and sources